30 April 2025 - Atzumi is the first and only product utilising the SMART (Simple MucoAdhesive Release Technology) platform which combines a proprietary advanced powder and device technology to simplify delivery of dihydroergotamine.

Satsuma Pharmaceuticals today announced that the US FDA has approved a 505(b)(2) new drug application for Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Read Satsuma Pharmaceuticals press release